Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +42.04%
#3 Pons Pons +20.06%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +16.94%
#6 o1.exchange o1.exchange +14.33%
#7 Ontology Gas Ontology Gas +13.66%
#8 Collect on Fanable Collect on Fanable +13.51%
#9 OpenGradient OpenGradient +11.97%
#10 Velvet Velvet +11.60%
Coin of the day
GEKKO GEKKO
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Rang in Aktien #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Aktienkurs
$14.07
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$1.18B
Veränderung (1 Tag)
-4.41%
Veränderung (1 Jahr)
145.13%
Land
US
Handel Corvus Pharmaceuticals, Inc. (CRVS)

Kategorie

Healthcare
Dividendenhistorie für Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (Aktienkürzel: CRVS) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Corvus Pharmaceuticals, Inc. (CRVS) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH